Galenica


Regulatory price cuts drag growth

13/03/19 -"Galenica reported FY 2018 revenue of CHF3,165m, up 0.8% and in line with consensus but missing our aggressive estimates. The strong growth of the health and beauty segment (H&B: revenue of ..."

Pages
45
Language
English
Published on
13/03/19
You may also be interested by these reports :
14/05/19
Q1 was mixed as sales missed expectations while earnings were slightly ahead of estimates. While Q2 is likely to be slow, particularly due to tough ...

13/05/19
Galenica (Add, Switzerland) has done little to keep investors happy since we last promoted this story in April 2018. The stock is up 5.4% in a sector ...

11/05/19
Following the strong Q1 19, we have hiked up our near-term estimates while also reducing the discount which had earlier been put in place for the ...

09/05/19
FY19 started on a weak note as Oticon Opn ran out of steam. However, with the introduction of successor, Opn S, in March 2019, momentum accelerated ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO